* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lixte Biotechnology Holdings's EV-to-EBIT
For the Biotechnology subindustry, Lixte Biotechnology Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lixte Biotechnology Holdings's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lixte Biotechnology Holdings's EV-to-EBIT falls into.
Lixte Biotechnology Holdings's current Enterprise Value is $5.24 Mil.
Lixte Biotechnology Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lixte Biotechnology Holdings's Enterprise Value for the quarter that ended in Mar. 2024 was $7.69 Mil.
Lixte Biotechnology Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lixte Biotechnology Holdings EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIXT has been successfully added to your 